Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment (Q81071034)
Jump to navigation
Jump to search
scientific article published on 11 April 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment |
scientific article published on 11 April 2008 |
Statements
Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment (English)
M Ohresser
G Salles
P Solal-Céligny
P Colombat